Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Innovative Treatment of Ovarian Cancer Based on Immunogene-modified T Cells (IgT)

NCT03184753 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.

NCT NCT03184753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03184753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Innovative Treatment of Ovarian Cancer Based on Immunogene-modified T Cells (IgT)
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Phase 1/2
Overall status
Terminated
Start date
May 1, 2025
Completion date
July 31, 2026
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer